enVVeno Medical Corporation (NVNO)
- Previous Close
3.7700 - Open
3.8000 - Bid 3.6000 x 100
- Ask 3.7600 x 100
- Day's Range
3.6100 - 3.8250 - 52 Week Range
2.0280 - 6.4800 - Volume
113,233 - Avg. Volume
94,747 - Market Cap (intraday)
63.656M - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1800 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.50
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
www.envveno.comRecent News: NVNO
View MorePerformance Overview: NVNO
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVNO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVNO
View MoreValuation Measures
Market Cap
66.11M
Enterprise Value
28.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.73
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.07%
Return on Equity (ttm)
-52.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.33M
Diluted EPS (ttm)
-1.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
38.94M
Total Debt/Equity (mrq)
2.56%
Levered Free Cash Flow (ttm)
-10.51M